Development of new H1 antihistamines: The importance of pharmacokinetics in the evaluation of safe and therapeutically effective agents

Current Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents

Volumn 4, Issue 5, 2005, Pages 451-464

  Whomsley, Rhys ^a   Benedetti, Margherita Strolin ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Cardiac safety; Cytochrome P 450; Drug interactions; H1 antihistamines; OATP; P glycoprotein; Pharmacokinetics; Sedation

Indexed keywords

ALCOHOL; ALUMINUM MAGNESIUM HYDROXIDE; ASTEMIZOLE; AZITHROMYCIN; CETIRIZINE; CIMETIDINE; CLARITHROMYCIN; DESLORATADINE; DIAZEPAM; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; FLUOXETINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; MACROLIDE; MIZOLASTINE; NEFAZODONE; OMEPRAZOLE; PROBENECID; RIFAMPICIN; RITONAVIR; TERFENADINE; UNINDEXED DRUG; VERAPAMIL;

ALLERGIC DISEASE; ANTICHOLINERGIC EFFECT; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FATALITY; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HUMAN; PHARMACOGENETICS; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

EID: 24644520680     PISSN: 15680142     EISSN: None     Source Type: Journal    
DOI: 10.2174/156801405774330394     Document Type: Review

References (153)

1. Kaufman, D.W.; Kelly, J.P.; Rosenberg, L.; Anderson, T.E.; Mitchell, A.A. JAMA, 2002, 287, 337.
2. McEvoy, G.K. Ed, American Hospital Formulary Service (AHFS) Drug Information 1996.
3. Van Cauwenberge, P.; De Belder, T.; Vermeiren, J.; Kaplan, A. Cli. Exp. All Rev., 2003, 3, 46.
4. Leurs, R.; Church, M.K.; Taglialatela, M. Clin. Exp. All., 2002, 32, 489.
5. Okerholm R.A.; Weiner, D.L.; Hook, R.H.; Walker, B.J.; Leeson, G.A.; Biedenbach, S.A.; Cawein, M.J.; Dusebout, T.D.; Wright, G.J.; Myers, M.; Schindler, V.; Cook, C.E. Biopharm. Drug Dispos., 1981, 2, 185.
6. Simons E.R., Simons K.J. Clin. Pharmacokinet., 36(5), 1999, 329-352.
7. Richards, D.M.; Brogden, R.N.; Heel, R.C.; Speight, T.M.; Avery, G.S. Drugs, 1984 28:38
8. Yun, C-H.; Okerholm, R.A.; Guengerich, F.P. Drug Metab. Dispos., 1993, 21, 403.
9. Patten, C.; Gagne, P.; Miller, V.; Crespi, C.; Thummel, K. Drug Metab. Rev., 2003, 35S1, Abstract 242.
10. Ling, K.H.; Leeson, G.A.; Burmaster, S.D.; Hook, R.H.; Reith, M.K.; Cheng, L.K. Drug. Metab. Dispos., 1995, 26, 631.
11. Matsumoto, S.; Hirama, T.; Matsubara, T.; Nagata, K.; Yamazoe, Y. Drug Metab. Dispos., 2002, 30, 1240.
12. Matsumoto, S.; Yamazoe, Y. Br. J. Clin. Pharmacol., 2001, 50, 1-11.
13. Yumibe, N.; Huie, K., Chen, K.J.; Snow, M.; Clement, R.P.; Cayen, N. Biochem. Pharmacol., 1996, 51, 165-172.
14. Zhang, Y-F.; Chen, X-Y.; Zhong, D.-F., Dong, Y.-M. Acta Pharmacol. Sin., 2003, 24, 715.
15. Whomsley, R.; Gerin, B.; Brochot, A.; Strolin Benedetti, M.; Baltes, E.; EAACI 2003; Paris, 7-11 June 2003, Abstract 953, data on file UCB.
16. Wood, S.G.; John, B.A.; Chasseaud, L.F.; Yeh, J.; Chung, M. Ann. Allergy, 1987, 59, 31-34.
17. Baltes, E.; Coupez, R.; Giezek, H.; Voss, G.; Meyerhoff, C.; Strolin, Benedetti, M. Fundam. Clin. Pharmacol., 2001, 15, 269-277.
18. Whomsley, R.; Collart, P.; Strolin Benedetti, M.; Baltes, E.; Nicolas, J.M. Drug Metab. Rev., 2003, 35(1), 30, abstract 59.
19. 1-antihistamine cetirizine, XXXIV EAACI congress Munich 2005, submitted.
20. Strolin Benedetti, M.; Plisnier, M.; Kaise, J.; Maier, L.; Baltes, E.; Arendt, C.; McCracken, N. Eur. J. Clin. Pharmacol., 2001, 57, 571-582.
21. Clarinex (Desloratadine) tablets, Prescribing information as of 2002, Physician Desk Reference, Clarinex (Desloratadine) Tablets, Approval Package, NDA Application No. 21-165, Approval date 12/21/2001.
22. Ghosal, A.; Yuan, Y.; Hapangama, N.; Su, A.D.; Alvarez, N.; Chowdhury, S.K.; Alton, K.B.; Patrick, J.E.; Zbaida, S. Biopharm. Drug Dispos., 2004, 25, 243-252.
23. Henz, B.M. Allergy, 2001, 56, 7.
24. Allegra (fexofenadine) prescribing information. Physician's Desk Reference. Montvale (NJ): Medical Economics, 2000, 1343.
25. Tannergren, C.; Petri, N.; Knutson, L.; Hedeland.M.; Bondesson, U.; Lennernas, H. Clin. Pharmacol. Ther., 2003, 74, 423.
26. Petri, N.; Tannergren, C.; Rungstad, D.; Lennernas, H. Pharm. Res., 2004, 21, 1398.
27. Cvetkovic, M.; Leake, B.; Fromm, M.F.; Wilkinson, G.R.; Kim, R.B. Drug Metab. Dispos., 1999, 27, 866.
28. Yasui-Furukori, N.; Uno, T.; Sugawara, K.; Tateishi, T. Clin. Pharmacol. Ther., 2005, 77, 17.
29. Robbins, D.K.; Castles, M.A.; Pack, D.J.; Bhargava, V. O.; Weir, S.J. Biopharm. Drug Dispos., 1998, 19; 455.
30. Lebrun-Vignes B.; Diquet B.; Chosidow O. Clin. Pharmacokin., 2001, 40(7), 501-507.
31. Simons, F.E.R. Clin. Exp. Allergy, 1999, 29(1), 3-8.
32. Wiseman, L.R.; Faulds, D. Drugs, 1996, 51(2), 260-277.
33. Van Cauwenberge, P.; De Belder, T.; Sys, L. Exp. Opin. Pharmacother., 2004, 5(8), 1807-1813.
34. Hashizume, T.; Imaoka, S.; Mise, M.; Terauchi, Y.; Fujii, T.; Miyasaki, H.; Kamataki, T.; Funae, Y. J. Pharmacol. Experim. Ther., 2002, 300, 298-300.
35. Simons, F.E.R.; In Middletons Allergy: Principles and Practice, 6th edition. Adkinson, Jr. N.R.; Yunginger, JW.; Busse, W.W.; Bochner, B.S.; Holgate, S.T.; Simons, F.E.R.; Mosby; 2003, Chapter 51, 834-869.
36. Matzke, G.R.; Halstenson, C.E.; Opsahl, J.A.; Hilbert, J.A.; Perentesis, G.; Radwanski, E.; Zampaglione, N. Clin. Pharmacol., 1990, 30, 364.
37. Haria, M.; Fitton, A.; Peters, D.H. Drugs, 1994, 48, 617.
38. Simons, F.E.R.; Bergman, J.N.; Watson, W.T.A., Simons, K.J. J Allergy Clin. Immunol., 1996, 98, 1062.
39. Tillement, J.P. Allergy, 1995, 50, 12-16.
40. Brée, F.; Thiault, L.; Gautier, G.; Strolin Benedetti, M.; Baltes, E.; Rihoux, J.P.; Tillement, J.P. Fund. Clin. Pharmacol., 2002, 16, 471-478.
41. Pauli, G.; Frossard, N. Revue Française d'Allergologie et d'immunologie clinique, 2004, 44, 194-198.
42. Monroe, E.W., Daly, A.F., Shalhoub, R.F. J. Allergy Clin. Immunol., 1997, 99, S798.
43. Wang, D.Y.; Hanotte, F.; De Vos, C.; Clement, P. Allergy, 2001, 56, 339-343.
44. Larbig, M.; Stamm, H.; Hohlfeld, J.; Krug, N. Levocetirizine but not desloratadine inhibits histamine-induced changes of nasal temperature measured by facial thermography; a pilot study. EAACI 2003, Paris, Abstract No.982.
45. Larbig, M.; Stamm, H.; Casper, A.; Hohlfeld, J.; Krug, N., EAACI 2004, Amsterdam, Abstract No.248.
46. Purohit, A.; Melac, M.; Pauli, G.; Frossard, N. Br. J. Clin. Pharmacol., 56, 388-394.
47. Purohit, A.; Duvernelle, C.; Melac, M.; Pauli, G.; Frossard, N. Ann. Allergy Asthma Immunol., 2001, 86, 387-392.
48. Devalia, J.L.; De Vos, C.; Hanotte, F.; Baltes, E. Allergy, 2001, 56, 50-57.
49. Grant, A. J.; Riethuisen, J-M.; Moulaert, B. DeVos, C. Ann. Allergy Asthma Immunol., 2002, 88, 190-197.
50. Dolen, W.K. Allergy Asthma Proc., 2004, 25, 85-87.
51. Greisner, W.A. Allergy Asthma Proc., 2004, 25, 81-83.
52. Meltzer, J. Allergy Clin. Immunol., 2004, 113, S26.
53. Roongapinun, S.; Wajajamreon, S.; Fooanant, S. J. Med. Assoc. Thai., 2004, 87, 551-556.
54. Purohit, A.; Melac, M.; Pauli, G.; Frossard, N. Br. J. Clin. Pharmacol., 2003, 56(4), 388-94.
55. Scheife, R.T.; Cramer, W.R. Consult. Pharm., 1996, 11, 1037.
56. Gillard, M.; Van Der Perren, C.; Moguilevsky, N; Massingham, R.; Chatelain, P. Molecular Pharmacology, 2002, 61(2), 391-399,.
57. Gillard, M.; Christophe, B.; Wels, B.; Peck, M.; Massingham, R.; Chatelain, P. Inflammation Research, 2003, 52, 1, S49-S50.
58. Molimard, M.; Diquet, B.; Strolin Benedetti, M. Fund. Clin. Pharm., 2004, 18, 399.
59. Molinoff, P.B.; Wolfe, B.B.; Weiland, G.A. Life Sci., 1981, 29, 427-443.
60. 1-antihistamines, XXXIV EAACI congress Munich 2005, submitted.
61. 1 antihistamine levocetirizine. XXXIV EAACI congress Munich 2005, submitted.
62. Boxenbaum, H. J. Pharm. Pharmaceut. Sci., 1999, 2, 89.
63. Kosoglou, T.; Salfi, M.; Lim, J.M.; Batra, V.K.; Cayen, M.N.; Affrime, M.B. Br. J. Clin. Pharmacol., 50(6), 2000, 581-589.
64. Brannan, M.D.; Reidenberg, P.; Radwanski, E.; Shneyer, L.; Lin, C.C.; Cayen, M.N.; Affrime, M.B. Clin. Pharmacol. Ther., 1995, 58(3), 269-278.
65. Kunta, J.R.; Sinko, P.J. Cur. Drug Metab., 2004, 5, 109.
66. Hait, W.N.; Gesmonde, J.F.; Murren, J.R.; Yang, J-M, Chen, H-X; Reiss, M. Biochem. Pharmacol., 1993, 45, 401.
67. Shon, J.; Lee, I.; Kim, M.; Chun, H.; Lee, J.; Yoon, Y.; Cha, S.; Kim, H.; Shin, J. Clin. Pharmacol. Ther., 2003, 73(2), P58 (PDI-B-2).
68. Walker, A.; Hoffer, C.; Sheffels, P.; Kharasch, E.D.R. Drug Metab. Rev., 2004, 36(1), 293, abstract 587.
69. Wang, Z.; Hamman, M.A.; Huang, S-M.; Lesko, L.J.; Hall, S.D. Clin. Pharmacol. Ther., 2002, 71(6), 414-420.
70. Dresser, G.K.; Bailey, D.G.; Leake, B.F.; Schwarz, U.I.; Dawson, P.A.; Freeman, D.J.; Kim, R.B. Clin. Pharmacol. Ther., 2002, 71, 11-20.
71. Hamman, M.A.; Bruce, M.A.; Haehner-Daniels, B.D.; Hall, S.D. Clin. Pharmacol. Ther., 2001, 69, 114-121.
72. Chen, C.; Hanson, E.; Watson, J.W.; Lee, J.S. Drug Met. Disp., 2003, 31, 312.
73. Imamura, Y.; Shimizu, K.; Yamashita, F.; Yamaoka, K., Takakura, Y.; Hashida, M. Biol. Pharm. Bull., 2001, 24, 930.
74. Nicolas, J-M.; Whomsley, R.; Collart, P.; Roba, J. Chem. Biol. Interact., 1999, 123, 63.
75. Obach, R.S.; Huynh, P.; Allen, M.C.; Beedham, C. J. Clin. Pharmacol., 2004, 44, 7.
76. Chaufour, S.; Le Coz, F.; Denolle, T.; Dubruc, C.; Cimarosti, I.; Deschamps, C.; Ulliac, N.; Delhotal-Landes, B.; Rosenzweig, P. Int. J. Clin. Pharmacol. Ther., 1995, 36(5), 286.
77. Gupta, S.; Banfield, C.; Lim, J.; Marino, J.M.; Clement, R.P.; Affrime, M.B.; Batra, V. J. Allergy Clin. Immunol., 2001, 107(2), S159 (Abstract 524).
78. Monahan, B.P.; Ferguson, C.L.; Killeavy, E.S.; Lloyd, B.K.; Troy, J.; Cantilena, L.R.; 1990, 264, 2788.
79. Shah, R. J. Clin. Pcol., 2002.
80. Vos, M.A.; Paulussen, D.C. Ann. Med., 2004, 36(Suppl 1), 35.
81. Sanguinetti, M.C.; Jiang, C.; Curran, M.E.; Keating, M.T. Cell, 1995, 81, 299-307.
82. Fermini, B.; Fossa, A.A. Nat. Rev. Drug Discov., 2003, 2, 439.
83. Roden, D.M. N. Eng. J. Med., 2004, 350, 1013.
84. Honig, P.K.; Wortham, D.C.; Zamani, K.; Conner, D.P.; Mullin, J.C.; Cantilena, L.R. JAMA, 1993, 269, 1513.
85. Pratt, C.M; Ruberg, S.; Morganroth, J.; McNutt, B.; Woodward, J.; Harris, S.; Ruskin, J.; Moye L. Am. Heart. J., 1996, 131, 472.
86. Crumb, W.J. J. Pharmacol. Exp. Ther., 2000, 292, 261.
87. Lindquist, M.; Edwards, R. Lancet, 1997, 349, 1322.
88. Taglialatela, M.; Pannaccione, A.; Castaldo, P.; Giorgio, G.; Zhou, Z.; January, C.T.; Genovese, A.; Marone, G.; Annunziato, L. Mol. Pharm., 1998, 54, 113.
89. Bernstein, D.L; Schoenwetter, W.F.; Nathan, R.A.; Storms, W.; Ahlbrandt, R.; Mason, J. Ann. Allergy Asthma Immunol., 1997, 79, 443.
90. Kreutner, W.; Hey, J.A.; Chiu, P.; Barnett, A. Arzneimittelforschung, 2000, 50, 441.
91. Sale, M.E.; Barbey, J.T.; Woosley, R.L.; Edwards, D.; Yeh, J.; Thakker, K.; Chung, M. Clin. Pharmacol. Ther., 1994, 56, 295.
92. Giudicelli, C.; Dricot, E.; Moati, F.; Strolin Benedetti, M.; Giudicelli, J-F. Fund Clin. Pharmacol., 2004, 18, 281.
93. Scrip, 2002, 2804, 19.
94. Matsumoto, S.; Yamazoe, Y. Br. J. Clin. Pharmacol., 51, 133.
95. Matsumoto, S.; Hirama, T.; Kim, H.J.; Nagata, K.; Yamazoe, Y. Xenobiotica, 2003, 33, 615,
96. Zhou, Z.; Vorperian, V.R.; Gong, Q.; Zhang, S.; January, C.T. J. Cardiovasc. Electrophysiol., 1999, 10, 836.
97. Cauffiez, C.; Klinzig, F.; Rat, E.; Tournel, G.; Allorge, D.; Chevalier, D.; Pottier, N.; Lovecchio, T.; Colombel, J.F.; Lhermitte, M.; Lo-Guidice, J.M.; Broly, F. Biochem. Pharmacol., 2004, 68, 2417.
98. Spiecker, M.; Darius, H.; Hankeln, T.; Soufi, M.; Sattler, A.M.; Schaefer, J.R.; Node, K.; Borgel, J.; Mugge, A.; Lindpaintner, K.; Huesing, A.; Maisch, B.; Zeldin, D.C.; Liao, J.K. Circulation, 2004, 110, 2132.
99. Timmerman, H. Allergy, 2000, (55 Suppl.) 60, 5.
100. Quach, T.T.; Duchemin, A.M.; Rose, C.; Schwartz, J.C. Eur. J. Pharmacol., 1979, 60, 391 396.
101. Passalacqua, G.; Bousquet, J.; Bachert, C.; Church, M.K.; Bindsley-Jensen, C.; Nagy, L.; Szemere, P.; Davies, R.J.; Durham, S.R.; Horak, F.; Kontou-Fili, K.; Malling, H.J.; van Cauwenberge, P.; Canonica, G.W. Allergy, 1996, 51, 666-675.
102. Timmerman, H. Clin. Exp. Allergy, 1999, 29, Suppl 3, 13-8.
103. Chishty, M.; Reichel, A.; Siva, J.; Abbott, N.J.; Begley, D.J. J. Drug Target, 2001, 9: 223.
104. Chen, C.; Hanson, E.; Watson, J.W.; Lee, J.S. Drug Metab. Dispos., 2003, 31(3), 312-8.
105. Doan, K.M.; Wring, S.A.; Shampine, L.J.; Jordan, K.H:; Bishop, J.P.; Kratz, J.; Yang, E.; Serabjit-Singh, C.J.; Adkison, K.K.; Polli, J.W. Pharmacology, 2004, 72, 92-98.
106. Tashiro, M.; Sakurada, Y.; Iwabuchi, K.; Mochizuki, H.; Kato, M.; Aoki, M.; Funaki, Y.; Itoh, M.; Iwata, R.; Wong; DF.; Yanai, K. J. Clin. Pharmacol., 2004, 44(8), 890-900.
107. Hindmarch, I.; Johnson, S.; Meadows, R.; Kirkpatrick, T.; Shamsi, Z. Curr. Med. Res. Opin., 2001, 17(4), 241-55.
108. Bjornsson, T.D.; Wagner, J.A.; Donahue, S.R.; Harper, D.; Karim, A.; Khouri, M.S.; Murphy, W.R.; Roman, K.; Schneck, D.; Sonnichsen, D.S.; Stalker, D.J.; Wise, S.D.; Dombey, S.; Loew, C. J. Clin. Pharmacol., 2003, 43(9), 943-67.
109. Committee ICoHS, Fed Regist., 1998, 63 (111), 31790.
110. Kim, K.; Johnson, J.A.; Derendorf, H. J. Clin. Pharmacol., 2004, 44(10), 1083-105.
111. Affrime, M.; Banfield, C.; Gupta, S.; Cohen, A.; Boutros, T.; Thonoor, M.; Cayen, M. Clin. Pharmacokinet., 2002, 41 Suppl 1, 21.
112. Choo, E.F.; McKinsey, J.; Dresser, M.D.; Mayo, G.; Kim, R.B.; Wilkinson, G.R.; Fexofenadine disposition is similar between caucasian and African-American men and women, American Society for Clinical Pharmacology and Therapeutics, 2000, 67, abstract 76.
113. Le Lamer, S.; Strolin Benedetti M.; Baltes. E. Pharmacokinetics of cetirizine in adults and children of different racial/ethnic categories, XXIII EAACI Congress, 12-16 June 2004, Amsterdam, Abstract book, Abstract No. 1055.
114. Burroughs, V.J.; Maxey, R.W.; Levy, R.A. J. Nat. Med. Assoc., 2002, 94, 1-26.
115. Ingelman-Sundberg, M. TIPS, 2004, 25, 193.
116. Dorne, J.L.C.M.; Walton, K.; Renwick, A.G. Food Chem. Toxicol. 2003, 41, 201.
117. Drescher, S.; Schaeffeler, E.; Hitzl, M.; Hofmann, U.; Schwab, M.; Brinkmann, U.; Eichelbaum, M.; Fromm, M.F. Br. J. Clin. Pharmacol., 2002, 53, pp. 526-534.
118. Verstuyft, M.; Schwab, E.; Schaeffeler, R.; Kerb, U.; Brinkmann, P.; Jaillon, et al. Eur. J. Clin. Pharmacol., 2003, 58, 809-812.
119. So-Young, Y.; Kyoung-Sup, H.; Hyeong-Seok L.; Jae-Yong, C.; Dal-Seok, O.; Jung-Ryul, K.; Hye-Ryung, J.; Joo-Youn, C.; Kyung-Sang, Y.; In-Jin, J.; Sang-Goo, S. Clin. Pharm. & Therapeut., Vol. 76, Issue 5, Nov., Pages 418-427.
120. Holgate, S.T.; Canonica, G.W.; Simons, F.E.; Taglialatela, M.; Tharp, M.; Timmerman, H.; Yanai, K. Clin. Exp. Allergy, 2003, 33(9),1305-24.
121. Begley, D.J. Pharmacol. Therapeut., 2004, 104, 29.
122. Prakash, A.; Lamb, H.M. Biodrugs, 1998, 10(1), 41-63.
123. Mesnil, F.; Dubruc, C.; Mentre, F.; Huet, S.; Mallet, A.: Thenot J.P. J. Pharmacokin. Biopharmac., 1997, 25(2), 125-147.
124. Deschamps, C.; Dubruc, C.; Mentre, F.; Rosensweig, P. Clin. Pharmacol. Ther., 2000, 68(6), 647-657.
125. Ghosal, A.; Yuan, Y.; Hapangama, N.; Su, D.A.(Iris); Alvarez, N.; Chowdhury, S.; Alton, K.B.; Patrick, J.E.; Sbaida, S. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxy-desloratadine. Drug Metab. Rev., 2003, 35(2), 51 (abstract 101).
126. Simons, E.R.; Simons, K.J. Clin. Pharmacokinet., 1999, 36(5), 329-352.
127. Hurst, M.; Spencer, C.M. Ebastine. Drugs, 59(4), 2000, 981-1006.
128. Yamaguchi, T.; Hashizurne, T.; Matsuda, M.; Sakashita, M.; Fujii, T.; Sekine, Y.; Nakashima, M.; Uematsu, T. Drug Res., 1994, 44, 59.
129. Hilbert, J.; Radwanski, E.; Weglein, R.; Van, L.; Perentesis, G.; Symchowicz, S.; Zampaglione, N. J. Clin. Pharmacol., 1987, 27, 694-698.
130. Ghosal, A.; Gupta, S.; Chowdhury, S.; Yuan, Y.; Lu, X.; Horne, D.; Su, A.D.(I); Alvarez, N.; Ramanathan, R.; Hanna, I.; Alton, K.B.; Patrick, J.E.; Zbaida, S. Drug Metab. Rev., 2003, 25, HS2, 186, abstract 371.
131. Strolin Benedetti, M.; Whomsley, R.; Baltes, E. Pharmacokinetic drug-drug interactions involving H1 antihistamines in humans in Clinical Immunology and Allergy in Medicine (Proceedings EAACI 2002 Congress), (Marone G. Ed.), JGC Editions, Naples (Italy), 2004, 625-632.
132. Peytavin, G.; Gontran, C.; Otoul, C.; Crémieux, A.C.; Moulaert, B.; Latour, F.; Melac, M.; Strolin Benedetti, M.; Farinotti, R. Lack of clinically relevant pharmacokinetic (PK) interaction between cetirizine (CTZ) and ritonavir (RTV) in male healthy subjects. 42nd ICAAC, 27-30 September 2002, San Diego, California, poster H-1718.
133. Sale, M.; Woosley, R.; Thakker, K.; Phillips, K.; Caridi, F.; Chung, M. A randomized, placebo-controlled, multiple-dose study to evaluate the electrocardiographic and pharmacokinetic interactions of azithromycin and cetirizine. J. Allergy Clin. Immunol., 1996, 74, 93 (P15).
134. Krishna, G.; Khalilieh, S.; Ezzet, F.; Marino, M.; Kantesaria, B.; Lim, J.; Batra, V. AAPS Pharm. Sci., 3 (3), 2001, 309.
135. Spencer, C.M.; Faulds, D.; Peters, D.H. Drugs, 1993, 46, 1055-1080.
136. Banfield, C.; Hunt, T.; Reyderman, L.; Statkevich, P.; Padhi, D.; Affrime, M. Clin. Pharmacokin., 2002, 41(1), 29-35.
137. Sale, M.; Woosley, R.; Thakker, K.; Phillips, K.; Caridi, F.; Chung, M. Effects of cetirizine and erythromycin, alone and in combination, on QT interval and pharmacokinetics in healthy subjects. J. Allergy Clin. Immunol., 1996, 74, 93 (P14).
138. Banfield, C.; Gupta, S.; Kantesaria, B.; Marino, M.; Batra, V.; Cayen, M.; Affrime, M.B. J. Allergy Clin. Immunol., 2001, 107(2), S161 (Abstract 529).
139. Banfield, C. Allergy, 2001, 56(68), 200 (Abstract 636).
140. Banfield, C.; Herron, J.; Keung, A.; Padhi, D.; Affrime, M. Clin. Pharmacokin., 2002, 41, S1, 37.
141. Allegra (Fexofenadine Hydrochloride), Approval Package, Application No.20-872, Approval date 2/25/2000, Clin Pharmacology Biopharmaceutics Review(s).
142. Lemma, G.L.; Hamman, M.A.; Hall, S.D.; Wang, Z. Clin. Pharmacol. Ther., 2003, 73(2), P16 (PI-56).
143. Mattila, M.J.; Aranko, K.; Kuitunen, T. Br. J. Clin. Pharmacol., 35(3), 1993, 272-277.
144. Vizcaino, S.; Cabellero, M.J.; Carrillo, J.A.; Benitez J. Methods Find. Exp. Clin. Pharmacol., 2003, 25(A), 170.
145. Mattila, M.J.; Kuitunen, T.; Pletan, Y. Eur. J. Clin. Pharmacol., 43(2), 1992, 174-184.
146. Abernathy, D.R.; Barbey, J.T.; Franc, J.; Brown, K.S.; Feirrera, I.; Ford, N.; Salazar, D.E. Clin. Pharmacol. Ther., 2001, 69(3), 96-103.
147. Abernethy, D.R.; Barbey, J.T.; Franc, J.; Brown, K.S.; Feirrera, I.; Ford, N.; Salazar, D.E. Clin. Pharmacol. Ther., 2001, 69, 96.
148. Van Rooij, J.; Schoemaker, H.C.; Bruno, R.; Reinhoudt, J.F.; Breimer, D.D.; Cohen, A.F. Br. J. Clin. Pharmacol., 1993, 35(6), 661-663.
149. Gillen, M.; Pentikis, H.; Rhodes, G.; Aubeneau M.; Scheinman S.; Duvauchelle T.; Morganroth J.; Chaikin P. J. Clin. Pharmacol., 1998, 38(9), 867.
150. Carr, R.; Edmonds, A.; Shi, H.; Locke, C.S.; Gustavson, L.E.; Craft, J.C.; Harris, S.I.; Palmer, R. Antimicrob. Agents Chemother., 42(5), 1998, 1176-1180.
151. Kraft, W.; Waldman, S.; Pequignot, E.; Greenberg, H. Clin. Pharmacol. Ther., 2002, 71(2), P49, abstract TPII-31.
152. Patat, A.; Stubbs, D.; Dunmore, C.; Ulliac, N.; Sexton, B.; Zieleniuk, I.; Irving, A.; Jones, W. Eur. J. Clin. Pharmacol., 1995, 48, 143-150.
153. Patat, A.; Perault, M.C.; Vandel, B.; Ulliac, N.; Zieleniuk, I.; Rosenzweig, P. Br. J. Clin. Pharmacol., 1995, 39, 31-38.